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METHODOLOGY
The early economic evaluation of novel 
biomarkers to accelerate their translation 
into clinical applications
Gimon de Graaf1* , Douwe Postmus1, Jan Westerink2 and Erik Buskens1
Abstract 
Background: Translating prognostic and diagnostic biomarker candidates into clinical applications takes time, is 
very costly, and many candidates fail. It is therefore crucial to be able to select those biomarker candidates that have 
the highest chance of successfully being adopted in the clinic. This requires an early estimate of the potential clinical 
impact and commercial value. In this paper, we aim to demonstratively evaluate a set of novel biomarkers in terms 
of clinical impact and commercial value, using occurrence of cardiovascular disease (CVD) in type-2 diabetes (DM2) 
patients as a case study.
Methods: We defined a clinical application for the novel biomarkers, and subsequently used data from a large 
cohort study in The Netherlands in a modeling exercise to assess the potential clinical impact and headroom for the 
biomarkers.
Results: The most likely application of the biomarkers would be to identify DM2 patients with a low CVD risk and 
subsequently withhold statin treatment. As a result, one additional CVD event in every 75 patients may be expected. 
The expected downstream savings resulted in a headroom for a point-of-care device ranging from €119.09 at a will-
ingness to accept of €0 for one additional CVD event, to €0 at a willingness to accept of €15,614 or more.
Conclusion: It is feasible to evaluate novel biomarkers on outcomes directly relevant to technological development 
and clinical adoption. Importantly, this may be attained at the same point in time and using the same data as used for 
the evaluation of association with disease and predictive power.
Keywords: Early health technology assessment, Translational research, Headroom analysis, Biomarkers, 
Cardiovascular disease risk
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and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Within the current paradigm of personalized medicine 
or precision medicine, many research efforts are aimed 
at identifying novel biomarkers [1–3]. Although the 
expectations of improved clinical practice through bet-
ter patient characterization remain high, it has long been 
recognized that the vast amount of biomarker research 
fails to live up to these expectations [4–10]. The fact 
that so few biomarkers are successfully translated from 
scientific discovery to clinical application entails a loss 
in health potential for patients and society. Moreover, 
resources from public and private investors allocated to 
research, development, and evaluation with the aim to 
improve patient outcomes appear wasted.
Biomarker discovery research has produced a vast 
body of literature on the association between bio-
marker and disease or outcome, and their diagnos-
tic or prognostic performance (i.e. discrimination or 
reclassification) [3, 11]. While this is often regarded as 
the end-point of discovery research, it is only the start 
of the translational research phase. Herein, a candidate 
biomarker is developed into a diagnostic or prognos-
tic technology and evidence required for its adoption 
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in the clinic is generated [8, 12–15]. Akin to clinical 
trials for pharmaceuticals, translational research is 
a long and complex trajectory requiring large finan-
cial investments, and will result in the rejection of a 
number of biomarker candidates [13]. Expert esti-
mates of the costs of developing and commercializing 
a new biomarker based diagnostic technology exceed 
$100M [16]. As a result, the large number of candi-
date biomarkers that could be developed into clinical 
applications far exceeds the resources available to do 
so. It is therefore of great importance to identify those 
candidate biomarkers that have the highest chance 
to succeed as a commercial product. This requires 
an estimate of their potential clinical value and cost-
effectiveness [11, 15, 17]. Unfortunately, currently 
employed methods for early biomarker evaluation pro-
vide little insight into clinical value [8, 9]. On the other 
hand, proposed methods for the assessment of clinical 
value such as (early) health economic modeling are too 
extensive to be applied for the selection of biomarker 
candidates [13–15, 17].
The PREdiction and early diagnosis of DIabetes and 
diabetes-related Cardiovascular Complications (PRE-
DICCt) project of the Center for Translational Molec-
ular Medicine (CTMM) was initiated to enhance the 
possibilities for prevention of DM2 and associated 
complications through the development of molecular 
diagnostics and molecular imaging of novel biomark-
ers [18]. Its research efforts identified three novel bio-
markers that were associated with incident CVD in 
DM2 patients: NT-proBNP, MMP-3, and Osteopontin. 
The association of these biomarkers with CVD inci-
dence, as well as their predictive power within a pre-
diction model have been described previously [19]. 
Whether further investments in translational research 
to develop diagnostic technologies based on these bio-
markers is warranted has yet to be determined.
In this paper, we aim to demonstrate an evaluation 
framework for the assessment of novel biomarkers 
on clinical impact and commercial value (headroom). 
Such an assessment can be used to support the selec-
tion of biomarker candidates for further development 
and R&D investment decisions during development. 
We claim that this may be achieved at the same point 
in time and using the same data as used for the evalua-
tion of predictive power or technical accuracy (i.e. data 
often available from discovery research). The CTMM 
PREDICCt project is used as a real-life case study to 
illustrate our framework. In our framework, we first 
define the application of the PREDICCt biomarkers 
in the clinical pathway and subsequently estimate the 
headroom of the markers in this application.
Clinical application definition
Numerous publications on the translation of biomarkers 
stress the importance of defining a clinical application 
early in the discovery and development process [10, 14, 
20]. This is because the value of any diagnostic or prog-
nostic test depends on the setting in which it is applied, 
and the decision it is used to support. For many published 
biomarkers no clinical application has been specified, or 
this has been defined so broadly that it cannot possibly 
be used to determine their potential (cost-)effectiveness 
or commercial value. In our case study project, two very 
broad possible applications of the discovered biomark-
ers had been proposed. The first was to identify low-risk 
DM2 patients for whom treatment could be postponed, 
the second was to identify high risk DM2 patients for 
whom treatment could be initiated or intensified [19]. 
With respect to the economic value of the biomarkers it 
has been proposed that an individual patient risk-based 
approach has the apparent potential to allocate treatment 
resources more efficiently and effectively [19].
To define a sufficiently detailed clinical application 
for the biomarkers, we gathered input from two clini-
cal experts: an internist specialized in vascular medicine 
(third author on this publication), and the resident car-
diologist that authored the publication describing the 
predictive power and possible clinical application of the 
biomarkers [19]. Under current international guidelines, 
DM2 patients are regarded as a high risk group for which 
the prescription of statins is advised [21–24]. In terms of 
risk, the so called high risk-group is defined by a 10-year 
CVD risk of 10% or higher. Recent studies indicated that 
there is a wide range of risk among the DM2 patient 
population [25, 26]. Consequently, for part of the DM2 
patient population the 10-year risk will likely fall below 
10%, in which case these patients could be considered 
to be over-treated under current guidelines. This could 
potentially be remedied by using a more accurate risk 
prediction based on the newly discovered biomarkers. 
The second application of the PREDICCt biomarkers—to 
identify high risk patients and initiate or intensify treat-
ment—is less likely to have a substantial clinical impact, 
due to the current clinical practice of CVD risk manage-
ment in DM2 patients. As DM2 patients already fall in 
the highest risk category according to most guidelines, 
and given the limited options available for more inten-
sive treatment, using the biomarkers as a risk stratifica-
tion tool to select very high risk patients for intensified 
treatment is not a viable option. Apart from intensify-
ing preventive treatment, high risk patients could also 
be screened for prevalent asymptomatic CVD. However, 
current guidelines clearly recommend against this prac-
tice, as it does not improve outcomes in patients that 
already receive preventive treatment [24].
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Headroom analysis
In this section, we aim to evaluate the clinical impact and 
headroom of a risk stratification tool based on the three 
biomarkers identified in the PREDICCt project when 
used to identify patients at low risk for CVD (10  year 
risk < 10%) and subsequently withhold statin treatment in 
these patients. The headroom of a new technology is the 
maximum net incremental cost for which its intended 
clinical application is still likely to be cost-effective [27]. 
We conducted a model-based evaluation using data from 
a large cohort study in The Netherlands. First, we devel-
oped a prediction model comprising the risk factors of the 
UKPDS risk engine [28] and the three novel biomarkers. 
Then, we estimated the impact of withholding treatment 
in those that fell below the risk cut-off using published 
data on the effectiveness of statins. Clinical impact was 
defined as the number of treatments withheld per addi-
tional CVD case. The headroom of the risk stratification 
tool was calculated for different levels of willingness to 
accept for one additional CVD event in the target popula-
tion. The willingness to accept is the minimum monetary 
amount that the healthcare payer must save or receive in 
order to be willing to forgo a certain health benefit. As 
the current status quo is to provide the intervention to 
all patients, the new technology leads to reduced health 
benefits at lower costs. Thus, willingness to accept is an 
appropriate measure of preference, rather than the more 
ubiquitous willingness to pay, which applies when an 
additional benefit can be obtained at an additional cost.
Study population
We used patient level data from the Secondary Manifes-
tations of ARTerial disease (SMART) study, a prospec-
tive cohort from The Netherlands. This study included 
patients that were referred to hospital with either mani-
fest artherosclerotic disease or for the management of 
cardiovascular risk factors, such as hypertension, hyper-
lipidaemia, and DM2. A detailed description of the study 
design has been published previously [29].
For the purpose of the current study, we selected 
patients with DM2 that had at least 5  years of fol-
low-up and no prior history of CVD at the time of 
inclusion (n = 389). DM2 was defined as a referral diag-
nosis of DM2, self-reported DM2, the use of glucose-
lowering agents, or a plasma glucose concentration 
of ≥ 7.0 mmol/L at baseline combined with the initiation 
of glucose-lowering treatment within 1 year after inclu-
sion. Patients were considered to have a prior history of 
CVD when their medical records stated cerebrovascular 
disease (transient ischemic attack, cerebral infarction, 
cerebrovascular ischemia, amaurosis fugax, or retinal 
arterial occlusion), peripheral vascular disease, coronary 
artery disease, or an abdominal aortic aneurysm. The 
characteristics of the study population included in our 
analysis are shown in Table 1.
Risk assessment
The 10-year CVD risk (defined as the occurrence of 
myocardial infarction, stroke or vascular death) for each 
patient in the study population was calculated using an 
internally developed risk prediction model based on the 
Fine and Gray methodology [30]. This model consisted of 
the risk factors in the UKPDS risk engine (age at diagno-
sis of DM2, sex, current smoking, HbA1c, systolic blood 
pressure, and the total cholesterol/HDL cholesterol 
ratio), and the three novel biomarkers. Missing values on 
these predictor variables in our dataset were dealt with 
using multiple imputation using the R-library MICE [31]. 
CVD risk was then computed by taking the average of the 
risk values predicted from each of the imputed datasets.
Effectiveness gap
We assumed that withholding statin treatment only has 
an impact on the incidence of CVD events and not on 
the non-CVD death rate. To estimate the clinical impact 
of this change in treatment policy, we fitted a compet-
ing risks model predicting the 10-year incidence of 
CVD events to the low-risk group. The model estimated 
cause-specific hazards for having a CVD event and for 
non-CVD death. These hazards were assumed to have a 
proportional hazard structure described by a Weibull dis-
tribution, and are described as follows:
and
where αc (0.098) and βc (4.879) are the shape and scale 





Table 1 Study population characteristics
Patient characteristics of the 389 patients without prior cardiovascular disease 
history in the SMART cohort
SD standard deviation, IQR interquartile range
Parameter Baseline value
Age [years, mean (SD)] 54.8 (11.0)
Female sex (%) 39.8
Age at diagnosis of type-2 diabetes [years, mean (SD)] 49.8 (11.6)
Currently smoking (%) 24.9
HbA1c [%, median (IQR)] 7.4 (6.6–8.6)
Systolic blood pressure [mmHg, mean(SD)] 145 (21)
Total cholesterol/HDL cholesterol ratio [median (IQR)] 4.6 (3.7–6.1)
NT-proBNP [pg/mL, median (IQR)] 92 (44–216)
MMP-3 [ng/mL, median (IQR)] 12.4 (8.1–17.3)
Osteopontin [ng/ml, median (IQR)] 17.0 (13.3–21.9)
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respectively, and αd (0.362) and βd (4.348) the shape and 
scale parameter of the Weibull distribution for non-CVD 
death, respectively. Lastly, HRno treatment is the hazard ratio 
for the effect of withholding treatment. A large trial on 
the effects of statins in DM2 patients reported a haz-
ard ratio of 0.76 [32], and in a meta-analysis of 14 rand-
omized trials a relative risk of 0.79 per mmol/L reduction 
in LDL cholesterol was found [33]. We therefore assumed 
that the effect of withholding statin treatment in our tar-
get population would lead to a hazard ratio of 1.25 for 
CVD events.  The effectiveness gap was defined as the 
increase in 10-year CVD incidence resulting from with-
holding statin treatment in the low-risk group. For each 
treatment strategy (prescribing statins and withholding 
statins), these cumulative incidences were calculated as
where
is the overall survival function.
Headroom
The costs of statin treatment were estimated to be €0.06 
per day  based on the average cost of simvastatin 40  mg 
in The Netherlands [34]. As DM2 patients will have peri-
odic checks with their general practitioner, as well as other 
prescription medication, costs for physician visits and 
prescription filling by pharmacies were assumed not to 
change when withholding statin treatment. The headroom 
of the point-of-care device was expressed as a function of 
the willingness to accept for one additional CVD event:
in which fLR is the fraction of patients in the DM2 popu-
lation with a CVD risk below 10%, ΔICVD is the change 
in CVD incidence as a result of withholding statin treat-
ment, WTA is the willingness to accept for one additional 
CVD event, and CT is the average per patient cost of sta-
tin treatment over the study horizon of 10 years. This was 
based on the average time patients DM2 patients are alive 
and did not experience a CVD event in our competing 
















H(WTA) = fLR(CT −�ICVD ·WTA)





t[hCVD(t) + hnonCVDdeath(t)]S(t)dt + 10 · S(10)


This willingness to accept was varied between €0 and the 
level at which the resulting headroom would be €0.
Sensitivity analysis
Apart from the willingness to accept, which was varied in 
the base case analysis, the headroom is to a large extend 
determined by the cost of treatment CT and the effects 
of withholding statin treatment on CVD incidence ΔICVD. 
We therefore assessed the impact on the headroom of 
changes in the per diem cost of statin treatment and the 
hazard ratio for the effect of withholding statin treatment 
in the low-risk group. Per diem costs of statin treatment 
were €0.06 in the base case and were varied by 25% in the 
sensitivity analysis (€0.045 and €0.075). We assessed two 
alternative scenarios for the effects of withholding stating 
treatment in the low-risk group. First, we assumed that 
the relative effectiveness of statin treatment is related to 
baseline CVD risk, meaning that low-risk patients have 
a lower relative risk reduction as a result of statin treat-
ment. This was implemented by using a hazard ratio 
for the effect of withholding statin treatment of 1.10, as 
opposed to 1.25 in the base case. In the second scenario 
we based the effects of statin treatment on a different 
study, which found a hazard ratio of 0.63 for the effect 
on CVD incidence in DM2 patients [35]. This was imple-
mented by using a hazard ratio for withholding treatment 
in the low-risk group of 1.58.
Results
The low-risk group (10-year CVD risk < 10%) thus iden-
tified consisted of 57.1% of the study population (Fig. 1). 
A large difference in the observed 10-year incidence 
was found between the two risk groups, indicating that 
the risk assessment model had a high predictive power 
(Fig. 1).
The predicted and observed 10-year CVD incidences 
are shown in Fig.  2. Withholding treatment in the low-
risk group increased the predicted cumulative CVD inci-
dence at 10  years by approximately 0.0133. This means 
that withholding treatment will lead to one additional 
CVD event in every 75 patients.
The average duration of treatment in the high risk 
group was estimated to be 9.52  years. This led to an 
estimated total average treatment cost over 10  years of 
€208.67. The headroom of a point-of-care device using 
the novel biomarkers was found to be €119.09 at a will-
ingness to accept of €0 (that is, no savings or monetary 
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gain would be required to accept an additional CVD 
event). The headroom became less than €0 when the will-
ingness to accept for one additional CVD event exceeded 
€15,614 (that is, an additional CVD event is accepted 
when a cost saving of more than €15,614 is realized).
The results of the sensitivity analysis are shown in 
Table  2. Varying the treatment effect of statins did not 
have an impact on the maximum headroom but did 
impact the willingness to accept level at which the head-
room becomes €0 (which increased when statin effects 
were less). Changes in the cost of statin treatment were 
reflected in the total cost of treatment and thereby had an 
impact on the maximum headroom (higher statin costs 
led to a higher headroom).
Discussion
In this study, we demonstrated that an early assessment 
of the clinical impact and commercial value (headroom) 
of novel biomarkers can be performed at the same time 
and using the same data as used to determine predic-
tive power and accuracy. We used a case study of bio-
markers for additional CVD risk stratification in DM2 
patients, more specifically a setting where such biomark-
ers would be used as a prognostic test to inform the 
decision on withholding statin treatment from low-risk 
patients. We found that withholding statin treatment in 
DM2 patients with a 10  year CVD risk of < 10% lead to 
an additional CVD event in every 75 patients for which 
treatment would be withheld. Furthermore, we found the 
headroom to be €119.09 in the optimal scenario from the 
industry perspective (that is, when no savings would be 
required in order to accept an additional CVD event). 
The headroom reduced to €0 when the willingness to 
accept would be €15,614 or more. When a larger cost 
saving is demanded for an additional CVD case (that is, 
there is a higher willingness to accept), a smaller part of 
the costs saved by withholding treatment is available to 
pay for the biomarker test. Headroom thus decreases as 
the willingness to accept increases. The willingness to 
accept at which the headroom is reduced to €0 was sen-
sitive to changes in both the effect of statin treatment 
in the low-risk group, as well as the cost of statin treat-
ment (lesser treatment effect and higher statin cost led to 
a higher willingness to accept at which headroom is €0). 
The maximum headroom was only sensitive to the cost of 
statin treatment (increased cost of statins led to a higher 
maximum headroom).
Our study is the first that estimates the clinical impact 
and commercial value of biomarkers for the estimation of 
CVD risk in DM2 patients, and one of the first to per-
form such an analysis for a biomarker technology before 
it is actually developed. A large body of literature exists 
demonstrating the predictive power and strength of asso-
ciation between biomarker and disease for many different 
types of biomarkers. Based on such results, there is often 
a positive and hopeful attitude towards novel biomarkers. 



































Fig. 1 Difference in observed 10-year cumulative cardiovascular 
disease (CVD) incidence (bar height) and group size (bar width) 
between the low risk group (estimated 10-year CVD incidence < 10%) 
and the high risk group (estimated 10-year CVD incidence > = 10%) 
based on the risk prediction model consisting of age at diagnosis 
of DM2, sex, current smoking, HbA1c, systolic blood pressure, and 
the total cholesterol/HDL cholesterol ratio, NT-proBNP, MMP-3, and 
Osteopontin
































Fig. 2 Comparison between the cumulative incidence of 
cardiovascular disease as predicted by the competing risk model and 
as observed in the SMART cohort
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These outcome measures, however, have little relation 
to the clinical, commercial, or economic value of a bio-
marker technology [11, 17]. Notably, it is not uncommon 
for a biomarker to be developed without a clear clinical 
implementation in mind. Without a clinical application 
definition, any assessment of clinical value or cost-effec-
tiveness is impossible. Such evidence is crucial for the 
adoption of a new biomarker technology in the clinic and 
by extension thereof its commercial success. As a result, 
many novel biomarkers fail to deliver on the high hopes 
that have been placed on them, and represent a waste 
of public and private research funds. Existing methods 
for the economic evaluation of biomarkers (and other 
healthcare innovations) such as early health economic 
modeling require more data, are computationally more 
complex, and as a result demand more time and finan-
cial resources to implement [15, 36]. Assessing multiple 
biomarker candidates, each with multiple possible appli-
cations, is often not feasible using those methods. Our 
less resource-demanding method employing data from 
biomarker discovery research and published literature in 
a computationally uncomplicated approach can provide 
relevant support in decision making.
The methods we employ are not completely novel. A 
number of methodological studies have dealt with the 
issue of biomarker assessment, some of which focus on 
the statistical aspects of such an assessment [37–40], 
while others describe assessment in a broader scope, 
including decisions on area of application and cur-
rent care comparators [27, 41, 42]. Our main goal was 
to demonstrate the applicability of such methods in a 
real-life setting of biomedical development. Likewise, a 
few recent studies demonstrated the potential for using 
health economic modeling as an alternative for RCTs to 
generate evidence on the cost-effectiveness of diagnostic 
tests [43, 44]. In several ways these studies have used an 
approach similar to ours. The main difference being that 
our method is aimed at an earlier stage of development—
immediately after discovery—where most biomarkers are 
falling out of the translational process. It thereby aims to 
primarily inform decisions on the direction of develop-
ment and investment, rather than adoption in the clinic.
Our case-study outcomes are difficult to compare to 
outcomes of other studies. Most economic evaluations 
use cost per quality adjusted life-year (QALY) as their 
primary outcome and determine cost-effectiveness by 
specifying a willingness to pay for an additional QALY. 
Accurately estimating the loss of QALYs as a result of 
withholding treatment would require a disease progres-
sion model, which is beyond the scope of this show-
case research. Moreover, the applicability of QALYs as 
an outcome measure in modeling studies for diagnostic 
test has previously been questioned [17]. A further issue 
regarding comparability with previous research is the 
fact that the willingness to accept is a concept not often 
encountered in health economic evaluations. A thresh-
old for willingness to accept an additional CVD event 
has never been specified. However, even in the absence 
of a relevant threshold the outcomes of our method can 
be informative for R&D and investment decisions. When 
a large headroom exists even when extremely unfavora-
ble (i.e. low in the case of willingness to pay, high in the 
case of willingness to accept) threshold values are used 
in the analysis, further investments in the development 
of the new technology are certainly warranted from an 
economic perspective. When no or a very small head-
room exists when favorable threshold levels are used, 
it is unlikely that the new technology will ever be cost-
effective when used in the evaluated application, and 
therefore it would not be wise to invest in further devel-
opment. By this token, due to the high costs and burden 
associated with cardiovascular events such as myocar-
dial infarction and stroke, it would appear unlikely that 
the willingness to accept for an additional CVD case will 
be sufficiently low to ever make a risk stratification tool 
in DM2 patients like the one analyzed in our case study 
a viable strategy. A threshold defined in willingness to 
accept is rare because most new interventions provide 
increased health outcomes at an additional cost. How-
ever, as many societies are increasingly concerned by 
Table 2 Results of the sensitivity analysis
HR hazard ratio for the effect of withholding statin treatment on cardiovascular disease, CVD cardiovascular disease, number needed to withhold = withholding 
treatment in this number of patients leads one additional cardiovascular disease event




Statin cost + 25% Statin cost − 25%
Additional CVD incidence 0.0134 0.0054 0.0307 0.0134 0.0134
Number needed to withhold 75 186 33 75 75
Total average cost of treatment €208.67 €208.67 €208.67 €260.83 €156.50
Headroom at WTA = €0 €119.09 €119.09 €119.09 €148.86 €89.31
WTA at which headroom = €0 €15,614 €38,867 €6795 €19,518 €11,711
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the sustainability of healthcare expenditures, we believe 
that it will become increasingly important to be able to 
express the willingness to forgo health benefits in return 
for cost reductions. These limitations notwithstanding, 
we believe that we have demonstrated that without using 
other evidence than datasets used for biomarker discov-
ery and published literature, it is possible to go beyond 
the usual evaluation of biomarkers on association with 
disease and predictive power and additionally give an 
insight in potential clinical impact and commercial value.
Abbreviations
CVD: cardiovascular disease; CTMM: Center for Translational Molecular Medi-
cine; DM2: type-2 diabetes mellitus; UKPDS: The United Kingdom Prospective 
Diabetes Study; QALY: quality-adjusted life year; WTA : willingness to accept.
Authors’ contributions
GDG and DP drafted, designed and executed the analysis. JW provided the 
data and clinical expertise for the case study and the writing of the manu-
script. GDG, DP, EB contributed to the interpretation of results. GDG wrote 
the first draft of the manuscript. All authors contributed to the editing of the 
manuscript and revising the manuscript based on reviewer comments, and 
approve of its final form. All authors read and approved the final manuscript.
Author details
1 Department of Epidemiology, University of Groningen, University Medical 
Center Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands. 
2 Department of Vascular Medicine, University Medical Center Utrecht, PO 
Box 85.500, 3508 GA Utrecht, The Netherlands. 
Acknowledgements
We thank the researchers of the Secondary Manifestations of ARTerial disease 
(SMART) study for making their data available for this research.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
The data that support the findings of this study are available from the SMART 
study group but restrictions apply to the availability of these data, which were 
used under license for the current study, and so are not publicly available. 
Data are however available from the authors upon reasonable request and 
with permission of the SMART study group.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Funding
This research was performed within the framework of CTMM, the Center for 
Translational Molecular Medicine http://www.ctmm.nl, project PREDICCt 
grant 01C-104, and supported by The Netherlands Heart Foundation, Dutch 
Diabetes Research Foundation and Dutch Kidney Foundation. The funding 
bodies had no influence on the design of the study, the collection, analysis, 
and interpretation of data, or the writing of the manuscript.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 21 January 2018   Accepted: 2 June 2018
References
 1. Ludwig J, Weinstein J. Biomarkers in cancer staging, prognosis and treat-
ment selection. Nat Rev Cancer. 2005;5:845–56.
 2. Nordström A, Lewensohn R. Metabolomics: moving to the clinic. J Neuro-
immune Pharmacol. 2010;5:4–17.
 3. Moons KGM. Criteria for scientific evaluation of novel markers: a perspec-
tive. Clin Chem. 2010;56:537–41.
 4. Lumbreras B, Parker LA, Porta M, Pollán M, Ioannidis JPA, Hernández-
Aguado I. Overinterpretation of clinical applicability in molecular diag-
nostic research. Clin Chem. 2009;55:786–94.
 5. Zolg W. The proteomic search for diagnostic biomarkers: lost in transla-
tion? Mol Cell Proteomics. 2006;5:1720–6.
 6. Ioannidis JPA, Panagiotou OA. Comparison of effect sizes associated with 
biomarkers reported in highly cited individual articles and in subsequent 
meta-analyses. J Am Med Assoc (JAMA). 2011;305:2200.
 7. Ioannidis JPA. Expectations, validity, and reality in omics. J. Clin. Epidemiol. 
2010;63:945–9.
 8. Ioannidis JPA. Is molecular profiling ready for use in clinical decision mak-
ing? Oncologist. 2007;12:301–11.
 9. Vickers AJ, Jang K, Sargent D, Lilja H, Kattan MW. Systenatic review of 
statistical methods used in molecular marker studies in cancer. Cancer. 
2008;112:1862–8.
 10. Williams PM, Lively TG, Jessup JM, Conley BA. Bridging the gap: moving 
predictive and prognostic assays from research to clinical use. Clin Cancer 
Res. 2012;18:1531–9.
 11. Bossuyt PMM, Reitsma JB, Linnet K, Moons KGM. Beyond diagnostic accu-
racy: the clinical utility of diagnostic tests. Clin Chem. 2012;58:1636–43.
 12. Pepe MS, Etzioni R, Feng Z, Potter JD, Lou M, Thornquist M, et al. Phases 
of biomarker development for early detection of cancer. Cancer. 
2001;93:1054–61.
 13. Sackett D, Haynes R. The architecture of diagnostic research. BMJ. 
2002;324:539–41.
 14. Van den Bruel A, Cleemput I, Aertgeerts B, Ramaekers D, Buntinx F. The 
evaluation of diagnostic tests: evidence on technical and diagnostic 
accuracy, impact on patient outcome and cost-effectiveness is needed. J 
Clin Epidemiol. 2007;60:1116–22.
 15. Horvath AR, Lord SJ, StJohn A, Sandberg S, Cobbaert CM, Lorenz S, et al. 
From biomarkers to medical tests: the changing landscape of test evalua-
tion. Clin Chim Acta. 2014;427:49–57.
 16. Dolginow D, Tynan K, Doheney N, Keeling P. Mystery solved! what is the 
cost to develop and launch a diagnostic? 2017. https ://www.diace utics 
.com/?exper t-insig ht=myste ry-solve d-what-is-the-cost-to-devel op-and-
launc h-a-diagn ostic . https ://www.slide share .net/Diace utics /how-much-
does-it-cost-to-launc h-and-comme rcial ize-a-compa nion-diagn ostic -test
 17. Durtschi A, Jülicher P. Assessing the value of cardiac biomarkers: going 
beyond diagnostic accuracy? Future Cardiol. 2014;10:367–80.
 18. CTMM Predicct. Biomarkers for the prediction and early diagnosis of dia-
betes and diabetes-related cardiovascular complications: output report. 
2015.
 19. van der Leeuw J, Beulens JWJ, van Dieren S, Schalkwijk CG, Glatz 
JFC, Hofker MH, et al. Novel biomarkers to improve the prediction of 
cardiovascular event risk in type 2 diabetes mellitus. J Am Heart Assoc. 
2016;5:e003048.
 20. Moynihan R, Henry D, Moons KGM. Using evidence to combat overdi-
agnosis and overtreatment: evaluating treatments, tests, and disease 
definitions in the time of too much. PLoS Med. 2014;11:11–3.
 21. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 
2016 European Guidelines on cardiovascular disease prevention in clini-
cal practice. Eur Heart J. 2016;37:2315–81.
 22. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, 
Blum CB, et al. 2013 ACC/AHA guideline on the treatment of blood 
cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report 
of the American College of Cardiology/American Heart Association Task 
Force on Practice Guidelines. J Am Coll Cardiol. 2013;63:2889–934.
 23. Fox CS, Golden SH, Anderson C, Bray GA, Burke LE, De Boer IH, et al. 
Update on prevention of cardiovascular disease in adults with type 2 
diabetes mellitus in light of recent evidence: a scientific statement from 
the American Heart Association and the American Diabetes Association. 
Diabetes Care. 2015;38:1777–803.
 24. American Diabetes Association. Standards of Medical Care in Diabe-
tes—2018. Diabetes Care. 2018;41:S1–159.
Page 8 of 8de Graaf et al. Cost Eff Resour Alloc  (2018) 16:23 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 25. Paynter N, Mazer N, Pradhan A, Gaziano J, Ridker P, Cook NR. Cardiovascu-
lar risk prediction in diabetic men and women using hemoglobin A1c vs 
diabetes as a high-risk equivalent. Arch Intern Med. 2011;171:1712–8.
 26. Kaasenbrood L, Boekholdt SM, Van Der Graaf Y, Ray KK, Peters RJG, Kaste-
lein JJP, et al. Distribution of estimated 10-year risk of recurrent vascular 
events and residual risk in a secondary prevention population. Circula-
tion. 2016;134:1419–29.
 27. Cosh E, Girling A, Lilford R, McAteer H, Young T. Investing in new 
medical technologies: a decision framework. J Commer Biotechnol. 
2007;13:263–71.
 28. Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a 
model for the risk of coronary heart disease in type II diabetes (UKPDS 
56). Clin Sci (Lond). 2001;101:671–9.
 29. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second 
manifestations of ARTerial disease (SMART) study: rationale and design. 
Eur J Epidemiol. 1999;15:773–81.
 30. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a 
competing risk. J Am Stat Assoc. 1999;94:496–509.
 31. Van Buuren S, Groothuis-Oudshoorn K. MICE: multivariate imputation by 
chained equations in R. J Stat Softw. 2011;45:1–67.
 32. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection 
Study of cholesterol-lowering with simvastatin in 5963 people with dia-
betes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–16.
 33. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy of cholesterol-
lowering therapy in 18 686 people with diabetes in 14 randomised trials 
of statins: a meta-analysis. Lancet. 2008;371:117–25.
 34. Zorginstituut Nederland. Medicijnkosten 2016. http://www.medic ijnko 
sten.nl. Accessed 2016 Nov 28.
 35. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, 
Livingstone SJ, et al. Primary prevention of cardiovascular disease with 
atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes 
Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 
2004;364:685–96.
 36. Annemans L, Genesté B, Jolain B. Early modelling for assessing health and 
economic outcomes of drug therapy. Value Heal. 2000;3:427–34.
 37. Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating 
the added predictive ability of a new marker: from area under the ROC 
curve to reclassification and beyond. Stat Med. Wiley Online Library. 
2008;27:157–72.
 38. Pencina M, Steyerberg EW, D’Agostino R Sr. Extensions of net reclassifica-
tion improvement calculations to measure usefulness of new biomarkers. 
Stat Med. 2011;30:11–21.
 39. Postmus D, De Graaf G, Hillege HL, Steyerberg EW, Buskens E. A method 
for the early health technology assessment of novel biomarker measure-
ment in primary prevention programs. Stat Med. 2012;31:2733–44.
 40. Steyerberg E, Vickers A, Cook NR, Gerds T, Gonen M, Obuchowski NA, 
et al. Assessing the performance of prediction models: a framework for 
some traditional and novel measures. Epidemiology. 2010;21:128–38.
 41. D’Agostino RB. Risk prediction and finding new independent prognostic 
factors. J Hypertens. 2006;24:643–5.
 42. Ijzerman M, Steuten LM. Early assessment of medical technologies to 
inform product development and market access: a review of methods 
and applications. Appl Health Econ Health Policy. 2011;9:331–47.
 43. Koffijberg H, van Zaane B, Moons KGM. From accuracy to patient out-
come and cost-effectiveness evaluations of diagnostic tests and biomark-
ers: an exemplary modelling study. BMC Med Res Methodol. 2013;13:12.
 44. Gerke O, Poulsen MH, Hoilund-Carlsen PF. Added value of cost-utility 
analysis in simple diagnostic studies of accuracy:18F-fluoromethylcho-
line PET/CT in prostate cancer staging. Am J Nucl Med Mol Imaging. 
2015;5:183–94.
